Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis
Table 1
The clinical profiles of the 50 pairs of donor/recipient in living donor liver transplantation.
Category
Donor
Recipient
value
Age (mean) years
20–54 (34.5)
48–72 (59.14)
0.000
Gender, male/female
26/24
22/28
>0.05
Before LDLT
After LDLT
ALT
AST
Bilirubin, total
HCV-RNA
Positive (%)
44 (88)
26 (52)
0.000
Negative (%)
6 (12)
24 (48)
0.000
Genotype
G1a
4
2
G1b
29
19
G2a
7
2
G2b
3
1
G3b
1
1
Uncertain
6
6
IL-28B rs8099917
TT (%)
43 (86.0)
41 (82)
41 (82)
>0.05
GT (%)
4 (8.0)
8 (16)
9 (18)
>0.05
GG (%)
3 (6.0)
1 (2)
0 (0)
>0.05
IL-28B rs12979860
CC (%)
7 (14.0)
1 (2)
4 (8)
>0.05
CT (%)
43 (86.0)
49 (96)
46 (92)
>0.05
TT (%)
0 (0)
0 (0)
0 (0)
Antiviral treatment strategy
a
b
c
d
e
a
b
c
d
e
rs8099917
TT (%)
22 (91.7)
4
4
4
6
3
4
4
4
6
3
GT (%)
1 (4.2)
1
2
1
2
GG (%)
1 (4.2)
rs12979860
CC (%)
2 (8.3)
1
1
2
CT (%)
22 (91.7)
4
5
4
5
5
4
5
4
5
3
TT (%)
0 (0)
24 recipients with HCV-RNA clearance after living donor liver transplantation and their antiviral treatment strategy including (a) no treatment; (b) history of pegIFN/RBV; (c) pretransplant pegIFN/RBV; (d) posttransplant pegIFN/RBV; (e) DAA (direct-acting antiviral agent).
